Saudi Arabia’s General Authority for Military Industries Announces a Fully Integrated Defense Show Starting March 2022
17.7.2020 00:05:00 EEST | Business Wire | Press release
Today the Kingdom of Saudi Arabia’s General Authority for Military Industries (GAMI) announced the launch of ‘World Defense Show’. The show will take center stage in the global defense show circuit, offering exhibitors and visitors the opportunity to participate in Saudi Arabia’s first truly integrated defense show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716006046/en/
His Excellency Ahmad Al Ohali, Governor of GAMI (Photo: AETOSWire)
Founded by GAMI, World Defense Show is focused on interoperability across air, land, sea, security innovative defense technologies and satellite defense systems. The inaugural event is scheduled to take place between 6th and 9th March 2022 and will then be held biennially in Saudi Arabia’s capital, Riyadh.
Speaking at a virtual press conference attended by international defense companies, GAMI’s Governor, His Excellency Ahmad Al Ohali stated: “As Technology is accelerating the rate at which the global defense industry is evolving, defense considerations are becoming increasingly complex. There is a need for a platform, which enables the defense community to convene and collectively consider the great opportunities and challenges that are facing us all. This is why we are launching World Defense Show, an innovative platform showcasing, through both live and virtual demonstrations, the possibilities that interoperability can provide across all five defense domains: Air, Land, Sea, Security and Satellite.”
He added, “There is no better place than Saudi Arabia to organize a defense event at this scale. A G20 country, the Kingdom is one of the world’s biggest defense spenders with a strategic location at the center of three continents, making it an ideal hub for defense trade and innovation. Saudi Arabia’s vision to localize 50% of its multi-billion-dollar defense expenditure by 2030 also presents massive opportunities to global industry OEMs and investors.”
GAMI has recruited a team of international experts to organize and run event operations.
Shaun Ormrod, Chief Executive Officer, World Defense Show, said: “Today’s launch of World Defense Show marks an exciting inflection point for the defense industry and a step forward in the ambition and scale of a defense trade show. Through World Defense Show we will demonstrate why Saudi Arabia is critical to the defense industry’s future. The platform will enable access to dedicated programs that support Saudi Arabia’s local businesses, it will leverage investment opportunities and encourage a new generation to aspire to work in the defense industry.” Mr. Ormrod is the former CEO of Farnborough Airshow with over 20 years of industry trade show expertise.
Over four days, World Defense Show will showcase comprehensive and interactive displays of integrated defense technology solutions, alongside conferences and thought leadership seminars focused on the next generation of defense. The show’s venue, estimated to accommodate 80,000 square meters of exhibition, hospitality and outdoor area, will feature demonstration facilities and virtual technological capabilities to showcase every defense domain on an unprecedented scale.
Video News Release embed and download link here
About World Defense Show
World Defense Show is a display and demonstration of integrated and innovation-driven defense solutions, set to serve as the global stage for defense interoperability. The inaugural World Defense Show will take place biannually starting March 2022 in Riyadh - Saudi Arabia, to showcase the latest in interoperable defense solutions. The event will be held in the presence of Saudi Arabia’s key leadership, international delegations and prominent industry decision makers from around the world.
About General Authority for Military Industries
The founder of World Defense Show, Saudi Arabia’s General Authority for Military Industries, is the regulator, enabler and licensor for the kingdom’s military industry. GAMI is responsible for domestic defense sector development in line with the national commitment to localize 50% of military manufacturing by 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716006046/en/
Contact information
Yara Abifaker, +971544285342
yara.abifaker@finsbury.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom